Lyell Immunopharma (LYEL) Cash from Operations (2020 - 2026)
Lyell Immunopharma (LYEL) posted Cash from Operations of 38510000.0 for Q1 2026, down 19.41% sequentially from 32251000.0 in Q4 2025, and up 29.65% YoY from 29703807.18 in Q1 2025.
Powered by 
Analysis
Lyell Immunopharma (LYEL) Cash from Operations (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Cash from Operations for 7 years, with the latest figure at 38510000.0 in Q1 2026.
- Quarterly Cash from Operations rose 29.65% year-over-year to 38510000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 133796000.0 (up 23.6% YoY) and the FY2025 annual result came in at 150024000.0, up 7.62% from the prior year.
- Cash from Operations slipped to 38510000.0 in Q1 2026 per LYEL's latest filing, from 32251000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 28577000.0 in Q3 2025 and troughed at 54738000.0 in Q1 2025.
- A 5-year average of 40245705.88 and a median of 39161000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations sank 45.55% in 2022, then jumped 31.73% in 2025.
- Over 5 years, Cash from Operations stood at 40267000.0 in 2022, then declined by 0.91% to 40635000.0 in 2023, then dropped by 16.26% to 47242000.0 in 2024, then surged by 31.73% to 32251000.0 in 2025, then decreased by 19.41% to 38510000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 38510000.0, 32251000.0, and 28577000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Lyell Immunopharma | 335.97 Mn | 335.97 Mn | - | -33.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -33.92 Mn |
| Mar 31, 2026 | -38.51 Mn |
| Dec 31, 2025 | -32.25 Mn |
| Sep 30, 2025 | -28.58 Mn |
| Jun 30, 2025 | -34.46 Mn |
| Mar 31, 2025 | -54.74 Mn |
| Dec 31, 2024 | -47.24 Mn |
| Sep 30, 2024 | -35.04 Mn |
| Jun 30, 2024 | -38.09 Mn |
| Mar 31, 2024 | -42.02 Mn |
| Dec 31, 2023 | -40.64 Mn |
| Sep 30, 2023 | -37.69 Mn |
| Jun 30, 2023 | -39.16 Mn |
| Mar 31, 2023 | -46.21 Mn |
| Dec 31, 2022 | -40.27 Mn |
| Sep 30, 2022 | -37.10 Mn |
| Jun 30, 2022 | -44.33 Mn |
| Mar 31, 2022 | -47.85 Mn |
| Dec 31, 2021 | -33.21 Mn |
| Sep 30, 2021 | -25.49 Mn |